NASDAQ:BOLD · NASDAQ Global Select
+$1.20 today
Vol 0.14M · Avg 0.22M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Management quality matters because capital allocation choices determine how much of Boundless Bio, Inc. earnings power becomes long-term shareholder value. Use this page to compare BOLD returns on capital, executive context, insider transactions, ownership signals, and growth trends against peers, then decide whether leadership appears disciplined, aligned, and capable of compounding through changing market conditions.
Return Metrics
ROE, ROIC & ROA over time
ROE
-59.0%
avg -9.7%
ROIC
-43.0%
avg -42.9%
ROA
-37.1%
avg -38.6%
Analysis
ROA is currently the strongest return metric at -37.1% versus its period average of -38.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Zachary Hornby | Chief Executive Officer, President & Director | $974,855.00 | — | 47 | $600,000.00 | 2.67% |
Robert C. Doebele | Chief Medical Officer | $690,275.00 | — | 55 | $230,000.00 | 1.02% |
Christian Hassig | Chief Scientific Officer | $673,000.00 | — | 54 | $230,000.00 | 1.02% |
James L. Freddo | Interim Chief Medical Officer | — | — | 71 | $32,000.00 | 0.14% |
Amy Berkley | Senior Vice President of Program Team | — | — | — | — | — |
Jessica Oien | Chief Legal Officer & Corporate Secretary | — | — | 55 | $220,000.00 | 0.98% |
Meredith Wesley | Chief Human Resources Officer | — | — | — | — | — |
David Hinkle | Senior Vice President of Finance, Controller & Corporate Treasurer | — | — | 64 | $140,000.00 | 0.62% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A0 analysts |
| Net Income | N/A | N/A | N/A | N/A0 analysts |
| EBIT | N/A | N/A | N/A | N/A0 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Who manages BOLD?
Boundless Bio, Inc. (BOLD) lists 8 active executives. The top listed executive is James L. Freddo, Interim Chief Medical Officer.
Are BOLD insiders buying or selling?
Recent insider activity shows net selling of $77.82M.
Explore More
Continue the stock analysis
Jump to another research area for this company.